Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance
Novartis has packaged and priced Kisqali – the second CDK4/6 inhibitor approved in the US – to compete with Pfizer's Ibrance, which made the mechanism of action the standard of care in untreated metastatic HR+/HER2- breast cancer.
You may also be interested in...
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
Pfizer's Ibrance has a strong lead in the CDK4/6 space, but Novartis' Kisqali and Lilly's Verzenio are looking to carve out their own niches, expand the category and move into earlier treatment settings. Another scramble is on as well, to answer the question: what comes next?